Alpha 2.0
Login Register
» Authors » C Gisselbrecht

C Gisselbrecht

Explore the profile of C Gisselbrecht including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 215
Citations 2863
Followers 0
Related Specialties
Oncology
Hematology
General Surgery
Top 10 Co-Authors
P Brice
E Lepage
B Coiffier
J P Marolleau
M Boiron
M Marty
C Haioun
C Ferme
H Tilly
A Bosly
Published In
Ann Oncol
J Clin Oncol
Nouv Rev Fr Hematol (1978)
Bone Marrow Transplant
Presse Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al.
Bone Marrow Transplant . 2016 Sep; 52(2):216-221. PMID: 27643872
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time...
2.
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers M, et al.
Ann Oncol . 2015 Dec; 27(3):390-7. PMID: 26681685
Background: Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy improves response rates and survival in patients with B-cell non-Hodgkin lymphoma (NHL). However, rituximab induces a transient B-cell depletion and...
3.
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al.
Bone Marrow Transplant . 2015 Sep; 51(1):51-7. PMID: 26367239
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in...
4.
Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study
de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Briere J, et al.
Ann Oncol . 2012 Jun; 23(12):3143-3151. PMID: 22700993
Background: Diffuse large B-cell lymphomas (DLBCLs) arising in specific extranodal sites have peculiar clinicopathologic features. Patients And Methods: We analyzed a cohort of 187 primary Waldeyer's ring (WR) DLBCLs retrieved...
5.
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
Haioun C, Mounier N, Emile J, Ranta D, Coiffier B, Tilly H, et al.
Ann Oncol . 2009 Jul; 20(12):1985-92. PMID: 19567453
Background: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT)...
6.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, et al.
Ann Oncol . 2008 Dec; 20(3):503-7. PMID: 19074215
Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of (18)fluorodeoxyglucose-positron emission tomography (PET) in posttreatment evaluation. The value of PET...
7.
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab
Jais J, Haioun C, Molina T, Rickman D, de Reynies A, Berger F, et al.
Leukemia . 2008 Jul; 22(10):1917-24. PMID: 18615101
Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional...
8.
Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy
Biasoli I, Franchi-Rezgui P, Sibon D, Briere J, De Kerviler E, Thieblemont C, et al.
Ann Oncol . 2008 Jun; 19(11):1915-20. PMID: 18552359
Background: Data on factors influencing inclusion of Hodgkin's lymphoma (HL) patients in randomized clinical trials (RCT) are limited and, for the present study they were analyzed in a RCT for...
9.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Morel P, Gaulard P, Gisselbrecht C, Ferme C, Salles G, Tilly H, et al.
Ann Oncol . 2007 Dec; 19(3):560-5. PMID: 18096567
Background: Overexpression of B-cell lymphoma 2 (bcl-2) protein is a simple biological adverse prognostic factor that could delimit the poor prognosis population candidate for improvement with high-dose therapy and autologous...
10.
Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
Gisselbrecht C, Bethge W, Duarte R, Gianni A, Glass B, Haioun C, et al.
Bone Marrow Transplant . 2007 Oct; 40(11):1007-17. PMID: 17922042
Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for...